CSI Market
Sign In | Register

Regeneron Pharmaceuticals Inc (REGN) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access REGN Annual Cash Flow →
Observing cash flow movements over recent quarters helps explain how Regeneron Pharmaceuticals Inc adapts cash usage as operating conditions change.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income2,024.10
Depreciation & amortization246.90
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories1.60
Research and Development in Process0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation500.40
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Marketable And Other Securities Gain Loss-25.00
Increase Decrease In Contract With Customer Liability99.60
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable837.30
Increase (Decrease) in Accounts Payable and Accrued Liabilities600.40
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets808.10
Other Working Capital0.00
Other Noncash Income (Expense)-110.50
Other net-132.20
Payments for (Proceeds from) Other Operating Activities-2,884.20
Discontinued operations0.00
Net Cash flow from Operating Activities1,891.90
Investing Activities
Capital Expenditures-470.80
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities4,755.10
Payments to Acquire Marketable Securities-4,706.00
Real Estate Investments0.00
Payments To Acquire Intangible Assets-48.90
Increase (Decrease) in Restricted Cash and Investments0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-99.90
Discontinued operations0.00
Net Cash Flow from Investing Activities-521.60
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-1,751.40
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-80.80
Other net0.00
Proceeds From Facility Lease Obligations-
Payments In Connection With Facility Lease Obligations-
Proceeds From Convertible Debt Net Of Issuance Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid-194.60
Net Cash Flow from Financing Activities-2,026.80
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow1,421.10
Total Cash Flow-657.70
4 historic quarters locked

Sign in to unlock the full Regeneron Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Regeneron Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000872589-26-000025

Figures are derived from filed reports and may be restated. Historical data is subject to revision.